Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for cancers driven by the RAS protein, one of the most common cancer drivers affecting approxima... Revolution Medicines is a late-stage clinical oncology company focused on developing targeted therapies for cancers driven by the RAS protein, one of the most common cancer drivers affecting approximately 30% of human cancer diagnoses. Founded in 2014 and headquartered in Redwood City, California, the company applies its proprietary RAS(ON) chemistry platform to create small-molecule inhibitors that target the active form of the RAS protein. The company's lead candidate, daraxonrasib, is advancing through multiple global Phase 3 trials for metastatic pancreatic ductal adenocarcinoma and non-small cell lung cancer, targeting multiple oncogenic RAS variants simultaneously. Revolution Medicines' pipeline also includes selective RAS(ON) inhibitors such as zoldonrasib for RAS G12D-mutant cancers and elironrasib for RAS G12C-selective applications. The company operates as a pre-commercial entity with no approved products, generating value through its high-throughput drug discovery platform and strategic partnerships designed to advance precision oncology therapies that move beyond earlier-generation RAS inhibitors.Show lessShow more

Disclosures ESG Data Financial Data

GHG Emissions Climate Targets EU Taxonomy Energy Waste Management

Data not available

No Climate Targets data disclosed by Revolution Medicines

We reviewed Revolution Medicines's website and available disclosure materials for the 2023 reporting period and did not identify any reported Climate Targets data.

If you would like us to review newly published materials or reassess the most recent disclosures, you can submit a data update request.

Would you like us to review Revolution Medicines's data?

Start your 30-day free trial to request a data review for Revolution Medicines.

Start Free Trial

Legal Center Contact Us